Opinion
The UK Risks Missing Out on the Next $1 Billion Cannabinoid Opportunity
A groundbreaking achievement is flying under the radar. Epidiolex, the first FDA approved cannabis-derived drug developed by GW Pharmaceuticals, is on track to surpass $1 billion in annual revenue—a feat that puts it in the league of blockbuster drugs like Humira and Lipitor.
Melissa Sturgess
February 11, 2025
